Cannabinoid-Monoterpene Topical Composition for Rapid Joint Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions that rely solely on cannabinoids provide only partial relief for neuropathic pain, particularly muscle and joint pain, and may have adverse side effects.
Innovation Solution
A topical pharmaceutical composition comprising monoterpenes, cannabinoids, ashwagandha extracts, and dimethyl sulfoxide (DMSO), formulated into a cream, gel, or lotion base, which includes specific ratios and preparation methods to enhance pain relief efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cannabinoid-based treatments are used for neuropathic pain, then some pain relief is achieved, but adverse side effects occur and relief is only partial
Solution Approach 1:
The patent combines multiple cannabinoids (CBD, THC, CBC, CBG) with terpenes (limonene, pinene, myrcene, caryophyllene) and ashwagandha extract in a synergistic formulation. This combination approach aims to enhance pain relief efficacy while reducing adverse side effects through the entourage effect, where multiple compounds work together to produce greater therapeutic benefit than individual cannabinoids alone.
Solution Approach 2:
The invention creates a composite topical composition integrating multiple pharmaceutical ingredients (cannabinoids, terpenes, ashwagandha) with specific ratios and formulations. This composite approach allows optimization of therapeutic effects while managing side effects through balanced composition, distinguishing it from single-component cannabinoid treatments.
2Reliability
If cannabinoid-based treatments are used for muscle and joint pain, then some analgesic effect is achieved, but the relief is not rapid or sufficient
Solution Approach 1:
The patent modifies key parameters of cannabinoid delivery by formulating a topical composition with specific concentrations (CBD 5-20%, THC 5-20%, terpenes 5-20%, ashwagandha 1-5%) and optimizing the vehicle system. This parameter optimization enables rapid absorption and onset of action while maintaining sufficient analgesic effect for muscle and joint pain.
Solution Approach 2:
The formulation uses terpenes and ashwagandha extract as intermediary components that enhance the penetration and absorption of cannabinoids into the target tissue. These intermediaries facilitate faster delivery and more rapid onset of analgesic effect compared to cannabinoid-only formulations.
3Ease of manufacture
If purified cannabinoids are used to achieve high purity, then manufacturing simplicity is improved, but the therapeutic efficacy is reduced due to loss of synergistic compounds
Solution Approach 1:
The patent extracts and isolates specific cannabinoids (CBD, THC, CBC, CBG) and terpenes (limonene, pinene, myrcene, caryophyllene) from cannabis plant material using controlled extraction methods. This selective extraction approach maintains the synergistic relationship between compounds while ensuring manufacturing feasibility and reproducibility of the formulation.
Solution Approach 2:
The formulation specifies precise parameter ranges for cannabinoid content (CBD 5-20%, THC 5-20%), terpene content (5-20%), and ashwagandha extract (1-5%). These parameter specifications enable standardized manufacturing while preserving the synergistic therapeutic efficacy through controlled composition rather than purified single compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition rapidly and effectively relieves muscle and joint pain without the risks associated with traditional cannabinoid-based treatments, demonstrating superior analgesic effects compared to CBD or CBD+THC creams.
Implementation Method 1
The composition rapidly and effectively relieves muscle and joint pain without the risks associated with traditional cannabinoid-based treatments, demonstrating superior analgesic effects compared to CBD or CBD+THC creams.
Data Source
AI summary
A topical pain relief composition has a base with a mixture of various components such as, but not limited to, a base, d-limonene, cannabinoids or a derivative thereof, ashwagandha extracts and dimethyl sulfoxide (DMSO).